XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.03
+3.35%Oct 26, 2026, 11:30 UTC
Xilio Therapeutics, Inc. announced that the first patient had been dosed in a Phase 1/2 clinical trial of XTX501 for metastatic non-small cell lung cancer.
Source:Oct 16, 2026, 14:00 UTC
Xilio Therapeutics, Inc. hired Yariv Houvras as chief medical officer.
Source:Aug 12, 2026, 11:30 UTC
Xilio Therapeutics received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate.
Source:Aug 12, 2026, 00:00 UTC
Xilio Therapeutics reported Q2 2026 collaboration and license revenue of $18.7 million, up from $8.1 million in Q2 2025, with a net loss of $6.4 million compared to a $15.8 million loss a year earlier.